Varoglutamstat is under clinical development by Vivoryon Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Varoglutamstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Varoglutamstat overview
PQ-912 is under development for the treatment of early stage mild dementia due to Alzheimer’s disease (AD), mild cognitive impairment, cancer and Huntington disease. It is administered orally. The drug candidate acts by targeting glutaminyl cyclase (QC).
Vivoryon Therapeutics overview
Vivoryon Therapeutics N.V. (Vivoryon) is a biopharmaceutical company that conducts clinical-stage research and development of new medicines for the treatment of cancers, Alzheimer’s and fibrotic indications. The company’s leads compound varoglutamstat (PQ912), a small molecule inhibitor of QPCT and QPCTL. pharmacology 1. Vivoryon other pipeline products include PBD-C06 a monoclonal antibody under evaluation that clears toxic pyroglutamate-Abeta. It also develops a therapeutic approach, dipeptidyl peptidase 4 inhibitors for the treatment of diabetes. It operates its offices in Halle and Munich, Germany. Vivoryon is headquartered in Halle, Germany.
For a complete picture of Varoglutamstat’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
